{"schema_version":"secwatch.filing_event.v1","accession":"0001636422-23-000095","form_type":"8-K","ticker":"HCAT","cik":"0001636422","company_name":"Health Catalyst, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.641539+00:00","generated_at":"2026-06-12T02:09:02.670864+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Health Catalyst Q2 revenue $73.2M beats midpoint; raises FY2023 guidance","bullets":["Total revenue $73.2M (+4% YoY) vs guidance midpoint of $72.3M.","Adjusted EBITDA $3.5M vs guidance midpoint of $2.75M; margin ~5% (+200 bps YoY).","Two large TEMS contracts signed: ~$50M and ~$60M, each with existing health system clients.","FY2023 revenue guidance raised to $290.5M–$295.5M; Adjusted EBITDA raised to $10.0M–$12.0M.","Net loss improved to $32.6M from $33.4M YoY; dollar-based retention reiterated at 102%–110%."],"urls":{"canonical":"https://secwatch.observer/filing/0001636422-23-000095","json":"https://secwatch.observer/filing/0001636422-23-000095.json","markdown":"https://secwatch.observer/filing/0001636422-23-000095.md","text":"https://secwatch.observer/filing/0001636422-23-000095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636422/000163642223000095/0001636422-23-000095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636422/000163642223000095/hcat-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:09:02.670864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"223286c3a0a8c296d2ef6cec075482065b4083a6","claim":"Health Catalyst, Inc. reported the quarter ended June 30, 2023 results: revenue $73.2 million. Guidance raised.","evidence_excerpt":"today reported financial results for the quarter ended June 30, 2023. “For the second quarter of 2023, we are encouraged by our financial results, including total revenue of $73.2 million and Adjusted EBITDA of $3.5 million, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, given that we are tracking slightly ahead of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636422/000163642223000095/0001636422-23-000095-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$73.2 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}